F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comShilpa Medicare Ltd is one of India’s leading pharmaceutical companies, known for its focus on oncology drugs, formulations, and active pharmaceutical ingredients (APIs). With a strong R&D base and growing presence in both domestic and international markets, Shilpa Medicare has become an emerging player in the pharma sector.
In this article, we’ll explore Shilpa Medicare Ltd’s share price target from 2025 to 2030, its business overview, key performance indicators, and long-term investment potential.
| Detail | Value |
|---|---|
| Open | ₹382.90 |
| Previous Close | ₹382.70 |
| Volume | 401,466 |
| Value (Lacs) | ₹1,579.37 |
| VWAP | ₹387.96 |
| Beta (Volatility) | 1.24 |
| Market Capitalization | ₹7,694 Cr |
| Day’s High | ₹398.00 |
| Day’s Low | ₹378.45 |
| UC Limit | ₹420.95 |
| LC Limit | ₹344.45 |
| 52-Week High | ₹500.00 |
| 52-Week Low | ₹277.50 |
| Face Value | ₹1 |
| Book Value Per Share | ₹121.29 |
| Dividend Yield | 0.25% |
| All-Time High | ₹500.00 |
| All-Time Low | ₹22.63 |
| 20D Avg Volume | 262,688 |
| 20D Avg Delivery (%) | 60.07% |
Founded in 1987, Shilpa Medicare Ltd is a fast-growing Indian pharmaceutical company engaged in the manufacturing of APIs and formulations with a strong presence in oncology, biologics, and novel drug delivery systems. The company’s products are supplied globally to regulated markets such as the US, Europe, and Japan.
With a focus on innovation, the company continues to invest in R&D to expand its product portfolio in high-margin therapeutic areas. Shilpa Medicare’s long-term growth story is supported by exports, capacity expansions, and partnerships with global pharma majors.
Leading player in oncology APIs and formulations.
Diversified product portfolio across therapeutic segments.
Strong export base with regulatory approvals from USFDA and EMA.
Market Cap of ₹7,694 Cr and Book Value of ₹121.29 per share.
Moderate volatility (Beta 1.24) suitable for long-term investors.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 44.23% |
| Retail & Others | 37.18% |
| Foreign Institutions | 10.92% |
| Mutual Funds | 4.26% |
| Other Domestic Institutions | 3.41% |
The shareholding structure shows a healthy mix of retail and institutional investors. A high retail participation indicates confidence from long-term individual investors, while foreign holdings provide stability and credibility to the company’s stock performance.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 390 | 430 |
| 2026 | 440 | 480 |
| 2027 | 470 | 520 |
| 2028 | 510 | 560 |
| 2029 | 550 | 610 |
| 2030 | 590 | 670 |
These projections are based on Shilpa Medicare’s financial strength, R&D pipeline, export performance, and expected growth in the Indian pharmaceutical industry.
By 2025, Shilpa Medicare’s stock is expected to remain stable within this range as the company continues to benefit from export-driven growth.
Why?
Increased demand for oncology APIs globally.
Expanding manufacturing capacity and regulatory approvals.
Investment Advice: Accumulate during market dips for medium-term returns.
In 2026, Shilpa Medicare may experience steady revenue growth driven by product launches and margin improvements.
Why?
Strong presence in regulated markets like the US and Europe.
Diversification into biologics and new formulations.
Investment Advice: Hold for long-term compounding; pharma remains a defensive sector.
The company’s R&D pipeline and strategic collaborations could strengthen profitability in 2027.
Why?
Higher operating efficiency and export realization.
Launch of high-margin oncology and specialty drugs.
Investment Advice: Continue SIP investments; suitable for risk-moderate investors.
By 2028, Shilpa Medicare may see stronger growth momentum with new product approvals in the US and EU markets.
Why?
Entry into biosimilars and next-generation therapies.
Improved return on capital employed (ROCE).
Investment Advice: Hold for long-term portfolio diversification.
A consistent growth trajectory supported by exports and new product launches can help the stock move higher.
Why?
Strong pipeline of high-value oncology formulations.
Increasing demand for specialty generics.
Investment Advice: Suitable for long-term investors seeking steady compounding.
By 2030, Shilpa Medicare could establish itself as a global oncology-focused company with a strong brand presence in international markets.
Why?
Sustained R&D innovation and capacity expansion.
Enhanced profit margins from value-added formulations.
Investment Advice: Excellent long-term investment for wealth creation and defensive stability.
Yes. Shilpa Medicare Ltd is a promising long-term investment option in the Indian pharmaceutical sector. Its focus on niche therapeutic segments, global market presence, and consistent growth potential make it a reliable pick for investors seeking both stability and future scalability.
Strong R&D and innovation-driven growth.
Expanding global footprint in regulated markets.
Healthy balance sheet and operational efficiency.
Long-term potential in oncology and specialty formulations.
Regulatory delays in product approvals.
Currency fluctuations affecting export margins.
Rising raw material costs or supply chain issues.
Shilpa Medicare Ltd is one of the most promising mid-cap pharmaceutical companies in India, showing consistent operational strength and a focus on innovation. With strong fundamentals, high promoter holding, and growing exports, the company is well-positioned for future expansion.
Currently, the stock trades around ₹382, and analysts expect it could reach ₹670 by 2030, provided R&D initiatives and international sales continue to perform strongly.
For investors looking for exposure to the pharmaceutical and healthcare sectors, Shilpa Medicare Ltd can be an attractive long-term opportunity.
What is the current share price of Shilpa Medicare Ltd?
Around ₹382.90 as of November 2025.
What is the 52-week high and low of Shilpa Medicare Ltd?
52-week high is ₹500.00 and 52-week low is ₹277.50.
Is Shilpa Medicare a good long-term investment?
Yes, it has strong fundamentals and consistent growth in the pharma space.
What is the market capitalization of Shilpa Medicare Ltd?
₹7,694 crore.
What is the dividend yield?
0.25% based on current market data.
Who are the major shareholders of Shilpa Medicare Ltd?
Promoters hold 44.23%, retail investors 37.18%, and foreign institutions 10.92%.
What is the face value of Shilpa Medicare shares?
₹1 per share.
What is the book value per share?
₹121.29 per share.
What is the expected target price of Shilpa Medicare in 2030?
Between ₹590 and ₹670, based on long-term growth estimates.
Is Shilpa Medicare a volatile stock?
It has a moderate volatility level with a beta of 1.24.
Disclaimer: This article is for educational and informational purposes only. All share price targets mentioned are hypothetical and for example purposes. Please consult a SEBI-registered financial advisor before making investment decisions.
Register & Login